Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291476 | 0.82 | CHRNB2 (0.38) | OPRL1ARGRM5OPRM1SLC6A2 | |
| SCHEMBL20037467 | 0.81 | OPRL1 (0.34) | OPRL1ARGRM5OPRM1SLC6A2 | |
| SCHEMBL20249269 | 0.78 | SLC6A2 (0.36) | OPRL1GRM5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20249275 | 0.76 | ALDH1A1 (0.39) | OPRL1LOX | |
| SCHEMBL20249234 | 0.75 | OPRL1 (0.34) | OPRL1ARSIGMAR1RAB9ASMN1; SMN2 | |
| SCHEMBL20249262 | 0.74 | SLC6A2 (0.51) | OPRL1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL20249413 | 0.74 | SLC6A2 (0.39) | OPRL1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL291894 | 0.74 | MAPT (0.43) | GRM5OPRM1SLC6A2SIGMAR1RAB9A | |
| SCHEMBL20249102 | 0.73 | CDK4 (0.43) | — | |
| SCHEMBL292131 | 0.73 | AR (0.43) | ARGRM5SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | OPRL1 4655/4885AR 1169/4885GRM5 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.